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Respiratory syncytial virus (RSV) surveillance is important to 
get insight into the burden of disease and epidemic pattern of 
RSV infection. This information is useful for healthcare resource 
allocation as well as the timing of preventive messages and 
palivizumab prophylaxis. For influenza surveillance the European 
Influenza Surveillance Scheme (EISS) was established in 1996, 
but no surveillance platform is available for RSV. To improve 
surveillance an RSV Task Group was established in 2003 and 
recommendations for RSV surveillance were developed. By 2008, 
progress was made for four out of six recommendations: the number 
of European countries testing specimens for RSV increased from 
six to fourteen; nose and/or throat swabs were generally used for 
detection of influenza and RSV; a total of 25 laboratories performed 
molecular testing for diagnosis and participated in a quality 
control assessment for RSV with an overall good performance; 
four of the ten countries that joined EISS in 2004 started reporting 
RSV detections in addition to influenza in the period 2004-8. 
Limited progress was achieved for standardising methods and the 
development of a sentinel surveillance system of representative 
hospitals. Improving RSV surveillance is possible by further 
harmonising the data collection and increased reporting of RSV.
Introduction
Respiratory syncytial virus (RSV) is the most important viral 
agent causing severe respiratory disease in young children [1-3]. 
RSV is also being recognised as a significant pathogen in adults 
[2,4] causing moderately severe respiratory disease especially in 
the elderly [5,6]. Influenza is widely recognised as a major cause of 
morbidity and mortality in humans [7,8]. Since RSV and influenza 
virus infections are associated with similar clinical symptoms [9] 
and frequently co-circulate around the same time of the year, 
there is substantial potential for confusion regarding the cause of 
influenza-like illness [10]. 
Influenza and RSV account for similar numbers of deaths in 
children and their impact varies by winter and age group. RSV 
is associated with more deaths than influenza in children aged 
1-12 months [11]. Excess deaths due to RSV and influenza virus 
infection have also been reported for the elderly population [5,8]. 
When comparing cause-specific mortality due to influenza virus and 
RSV infection in all ages, it has been estimated that most deaths 
were associated with influenza A(H3N2) viruses, followed by RSV, 
influenza B, and influenza A(H1N1) [8]. 
While influenza is on the list of communicable diseases that must 
be covered by the European Community network for surveillance, 
RSV is not on this list [12]. Nonetheless, RSV causes considerable 
burden of disease and RSV surveillance is important for determining 
the burden of illness in all age groups and in defining seasonality 
and epidemic pattern. This facilitates the preparation of hospital 
settings to receive more children and to define the timing of the start 
of palivizumab prophylaxis [13]. Palivizumab can be administered 
as passive immunoprophylaxis and is the only strategy that has been 
demonstrated to reduce RSV hospitalisations in high-risk children 
[14]. For real-time influenza surveillance the European Influenza 
Surveillance Scheme (EISS), a collaborative multinational project, 
was established in 1996 [15], but no such scheme was available 
for other respiratory viruses including RSV. Since RSV and influenza 
infections typically occur in the winter, EISS made it possible to 
report RSV detections into the EISS database, on a voluntary basis, 
from 1996 until September 2008. 
In 2003 an RSV Task Group was established within EISS to 
explore the possibility to design a comprehensive RSV surveillance 
scheme within the EISS framework. This Task Group was composed 
of four epidemiologists and two virologists. Three meetings were 
organised between July 2003 and January 2006 and updates 
on the activities were presented to the EISS group during the 
EISS Annual Meetings. A retrospective analysis was carried out. 
Additionally, RSV surveillance recommendations were published in 
2006 [16], and are presented below:
1. Specimens collected as part of an influenza surveillance 
programme should also be tested for RSV.
2. Both combined nose/throat swabs and nasal pharyngeal 
aspirates are acceptable for RSV diagnosis.
3. The application of molecular techniques such as real 
time PCR in the diagnosis of respiratory disease has been 
demonstrated and we advocate this technique for RSV 
detection.
4. Further developments are encouraged on the use of 
standardised methods and laboratory techniques.
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5. The development of a sentinel approach of representative 
hospitals should be considered.
6. New countries joining EISS are encouraged to integrate RSV 
surveillance alongside influenza surveillance.
Our objective was to assess whether the RSV reporting within 
EISS in the period 2004-2008 complied with these surveillance 
recommendations, and to describe the detection and reporting of 
seasonal influenza and RSV infections in six selected countries in 
Europe.
Methods 
Data collection in EISS
EISS was based on an integrated clinical and virological 
surveillance model. Sentinel primary care physicians reported 
weekly the number of new cases of influenza-like illness and/or 
acute respiratory infections and obtained respiratory specimens 
from a sample of patients for laboratory testing. The specimens 
were tested for influenza and in several countries for RSV as well. 
Weekly consultation rates and laboratory test results were entered 
by the national surveillance networks into the EISS database via an 
internet-based system [17]. Non-sentinel, mainly hospital-based 
data for influenza and RSV were also collected, but will not be 
presented in this paper. 
Since September 2008, European influenza surveillance has 
been carried out by the European Centre for Disease Prevention 
and Control (ECDC) and involves all 27 European Union Member 
States and Norway. Three other countries Serbia, Switzerland and 
Ukraine are reporting data to World Health Organization (WHO) 
Regional Office for Europe. 
This paper presents a descriptive study. Surveillance data for 
seven winter seasons (2001-2 to 2007-8; week 40-20) in the 
EISS database were screened for RSV detections by country. The 
database containing virological detections of RSV and influenza was 
downloaded by September 2008. An RSV reporting country was 
defined as a country that reported at least 10 sentinel specimens 
positive for RSV from 2001-2008. With this method the progress 
for recommendation 1 and 6 could be assessed. For the other 
T a b l e  2
Number of sentinel influenza and respiratory syncytial virus (RSV) detections by country in the period 2001-2008
Country
Number of RSV detections per season
mean (range)
Number of influenza 
detections per season
mean (range)
Total number of RSV and 
influenza detections
mean (range)
Percentage of RSV cases (%)*
(range)
Czech Republic 18 (5-30) 206 (83-311) 223 (102-327) 8 ( 3-19 )
France 145 (47-227) 1053 (824-1374) 1198 (947-1601) 12 (4-18 )
Germany 43 (12-138) 1129 (553-2145) 1172 (568-2172) 4 (1-10)
The Netherlands** 12 (1-19) 121 (15-142) 133 (16-153) 4 (0-16)
Slovenia 6 (1-12) 101 (69-132) 106 (77-135) 5 (1-12)
UK-England 44 (14-125) 231 (82-432) 275 (107-477) 16 ( 8-56)
UK-Scotland 23 (14-35) 101 (31-193) 123 (50-220) 18 (11-38)
* The percentage of RSV cases in relation to the total number of samples that tested positive for either influenza or RSV.
** No RSV detections were reported for the Netherlands in the winters of 2001-2 and 2004-5. 
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Reporting of respiratory syncytial virus (RSV) and influenza data to the European Influenza Surveillance Scheme (EISS) in 
the period 2001-2008
Season Number of countries reporting RSV* Number of countries reporting influenza Number of RSV detections Number of influenza detections
2001-2 6 18 203 2276
2002-3 8 19 335 3787
2003-4 12 22 143 2732
2004-5 12 23 557 5483
2005-6 14 28 803 3171
2006-7 14 30 888 5077
2007-8 13 31 929 5076
*Countries reporting RSV:
2001-2: CZ, FR, DE, SI, CH, UK-E, UK-S.
2002-3: CZ, FR, DE, NL, SK, SI, CH, UK-E, UK-S.
2003-4: CZ, FR, DE, NL, SK, SI, CH, UK-E, UK-S.
2004-5: AT, CZ, DK, FR, DE, IT, LU, PL, RO, SI, CH, UK-E, UK-S.
2005-6: AT, CZ, DK, EE, FI, FR, DE, IT, LU, NL, PL, RO, SI, UK-E, UK-S.
2006-7: AT, CZ, DK, EE, FI, FR, DE, IT, LU, NL, PL, RO, SI, UK-E, UK-S.
2007-8: AT, HR, CZ, DM, EE, FI, FR, DE, LU, NL, PL, SI, UK-E, UK-S.
Abbreviations: Austria (AT), Croatia (HR), Czech Republic (CZ), Denmark (DK), Estonia (EE), Finland (FI), France (FR), Germany (DE), Italy (IT), Luxembourg (LU), 
the Netherlands (NL), Poland (PL), Romania (RO), Slovenia (SI), Slovakia (SK), Switzerland (CH), UK-England (UK-E), UK-Scotland (UK-S).
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recommendations the progress was summarised by collecting 
relevant data from inventories and a quality control assessment.
RSV detections: six countries
Country selection
Data from the Czech Republic, France, Germany, Netherlands, 
Slovenia and the United Kingdom (UK) (represented by England 
and Scotland) were assessed to describe the RSV surveillance 
in these countries. All had reported data for at least five winter 
seasons. Sentinel primary care physicians included general 
practitioners (GPs) in the United Kingdom and the Netherlands, 
and GPs and paediatricians in the Czech Republic, France, and 
Germany, and GPs, paediatricians and specialists in Slovenia. The 
sentinel doctors represented 1-5% of all physicians working in 
the country.
Case definition
Data on new cases were based on reporting of consultations for 
influenza-like illness (ILI) in the Netherlands, Slovenia and United 
Kingdom. Consultations for acute respiratory infections (ARI) were 
collected in France and Germany. From 2001-2 to 2004-5 the 
Czech Republic reported the number of new cases of ARI, and 
from 2005-6 onwards they reported cases of ILI in addition to 
ARI [18]. Case definitions for ARI and ILI differed slightly between 
countries [19]. The type of specimen that was collected (nose 
and/or throat swab) as well as transport conditions were similar 
[20]. Samples were generally collected within five days after onset 
of symptoms and systematically tested for both influenza virus 
and RSV in all countries. In Germany, only specimens of children 
aged 0-3 years were tested for RSV. Cases were defined positive 
for RSV or influenza when at least one laboratory test yielded a 
positive result. Between-country comparisons will not be made due 
to methodological differences. 
Results 
Recommendation 1
Specimens collected as part of an influenza surveillance 
programme should also be tested for RSV.
Seventeen countries had reported RSV detections in the period 
2001-2008: Austria, Croatia, Czech Republic, Denmark, Estonia, 
Finland, France, Germany, Italy, Luxembourg, Netherlands, Poland, 
Romania, Slovenia, Slovakia, Switzerland, UK- England and 
Scotland. Since England and Scotland have their own sentinel 
surveillance systems, these are presented separately in this paper. 
The number of countries reporting influenza data increased from 
18 in 2001-2 to 31 in the winter of 2007-8 (Table 1).
In 2001-2 only six countries reported RSV detections in addition 
to influenza, but their number gradually increased, particularly 
around 2003-4, among both countries that had participated since 
2001 and new members (see also results for recommendation 
6). From 2005-6 no further increase in the number of countries 
reporting RSV was observed (Table 1).
Recommendation 2
Both combined nose/throat swabs and nasal pharyngeal aspirates 
are acceptable for RSV diagnosis. 
Different types of specimens are used for detection of influenza 
and RSV [21]. Generally the nasopharyngeal aspirates have a high 
sensitivity, and are often used in a hospital setting. Easier to use 
and less painful are nasal/nasopharyngeal swabs [22]. An inventory 
carried out in 2002 indicated that in sentinel surveillance systems 
in Europe nose and/or throat swabs were taken [20]. Twelve out 
of 20 national networks collected combined nose/throat swabs. 
The remaining networks collected either nasopharyngeal, nasal, 
or throat swabs. In addition, three networks took blood samples 
and one network obtained nasal aspirates [20]. Since all countries 
had already used the recommended type of respiratory sample and 
fulfilled the recommendation, no progress was assessed after 2002.
Recommendation 3
The application of molecular techniques such as real time 
polymerase chain reaction (PCR) in the diagnosis of respiratory 
disease has been demonstrated and this technique is advocated 
for RSV detection.
In 2006, laboratories were invited to participate in a quality 
control study for molecular methods. Of the 33 laboratories 
participating in EISS, 25 performed this technique with an 
overall performance of 88% correct results [23]. The majority (22 
out of 25) of laboratories used an in-house molecular assay. In 
particular, real time PCR and nested PCR assays provided the 
highest performance scores (93% correct score; range 70-100) and 
were used in 19 laboratories. Three laboratories used commercial 
assays and the percentage of correct results ranged from 50% to 
80% [23]. 
Recommendation 4
Further developments in the use of standardised methods and 
laboratory techniques are encouraged.
Limited progress was made in standardising methods. Only 
for influenza, not RSV, laboratory protocols were shared and 
standardised reagents were made available via the EISS website. 
However, with the application of molecular methods, as indicated in 
recommendation 3, and quality control assessment of this method, 
the quality of laboratory testing of RSV is ascertained.
Recommendation 5
The development of a sentinel system of representative hospitals 
should be considered.
No efforts were made to develop a European sentinel surveillance 
system consisting of representative hospitals, though national 
initiatives may have been undertaken. For example, a laboratory-
based surveillance for RSV involving different hospital laboratories 
in Slovenia was implemented in 2006 [24].
Recommendation 6
We recommend the new networks joining EISS to integrate RSV 
surveillance alongside influenza.
Ten new countries became members of EISS between 2004 and 
2008: Austria, Bulgaria, Croatia, Estonia, Finland, Cyprus, Greece, 
Hungary, Ukraine and Serbia [25]. Of these, four countries followed 
the recommendation and started reporting RSV data (Table 1).  
RSV detections: six countries
To illustrate the data that were collected by EISS, we present the 
results of RSV detections for six countries. All countries reported at 
least five seasons of data, which provided insight in the occurrence 
of RSV in these countries. RSV and influenza detections are 
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presented in Table 2. The percentage of RSV-positive specimens 
largely differed by season, e.g. from 3% to 19% in the Czech 
Republic (Table 2). For all seasons and countries together the 
percentage of RSV-positive specimens varied from 4% in Germany 
and the Netherlands to 16-18% in the United Kingdom. RSV 
activity usually started a few weeks before the onset of influenza 
activity (data not shown). The data collected are useful to describe 
the seasonality of RSV and show that RSV is detected in patients 
with ILI and/or ARI.
Discussion and conclusion
Progress in RSV surveillance was made in the period 2001-
2008, with the most obvious increase in the number of reporting 
countries during the time the RSV Task Group was active, between 
2003-2006. Progress was made particularly in terms of the 
number of countries testing specimens for RSV and the use of 
molecular techniques. The results for the six countries that had 
reported at least five years of data showed that RSV surveillance 
and reporting is feasible in Europe. The overall percentage of 
RSV-positive specimens for the Czech Republic, France, Germany, 
Netherlands, Slovenia and the UK amounted to 4-18% indicating 
that a substantial number of patients who consulted their sentinel 
physician with influenza-like illness or acute respiratory infection 
actually had an RSV infection. The EISS surveillance is real time 
and therefore can be relevant for timing of the influenza and RSV 
peak and providing insight into the morbidity and seasonality of 
these respiratory illnesses.
Limited progress was made for recommendation 4 on the use 
of standardised laboratory methods. With the use of mainly in-
house developed methods that perform well [23], the standardising 
of methods was not further explored. The rationale was that 
standardising methods is important and is encouraged by sharing 
protocols, but more important is the ability of the laboratory test 
to correctly identify RSV. Furthermore, limited progress was made 
for recommendation 5 on the development of a sentinel approach 
of hospitals. This recommendation was ranked as a lower priority 
because non-sentinel data from hospitals are currently being 
collected. The non-sentinel data could be used for the future 
establishment of a sentinel laboratory monitoring system and would 
then need to be assessed for representativeness and quality of 
data collection.
In this paper we presented data on sentinel RSV and influenza 
detections. Relatively low numbers of positive RSV tests were 
reported and this is therefore a limitation. In addition to sentinel 
data, RSV reports from non-sentinel sources, mainly derived from 
hospitalised infants are also available and these can provide insight 
into the epidemic peak of RSV during wintertime. We think that 
both sources of data are important and complement each other. 
Sentinel data highlights the occurrence of RSV in the community, 
where it is an important confounder in influenza surveillance. And 
hospital-based data present the circulation of RSV in more severe 
cases and high-risk groups.
The limitations of the sentinel influenza surveillance carried 
out by EISS are related to differences in case definitions [19], 
sampling guidelines and laboratory techniques among the different 
countries [20]. Some difficulty in obtaining swabs from all age 
groups has been reported, especially for young children in the 
Netherlands and the elderly in the Netherlands and France [16]. 
Another limitation is that we could not further investigate other 
possible causes of respiratory infections such as rhinovirus, 
adenovirus and coronavirus [26,27] and human metapneumovirus 
[28]. Country resources however may limit the extension of testing 
for other viruses in addition to influenza and RSV. Furthermore, no 
comparison regarding the occurrence of RSV and influenza between 
the different countries could be made because of differences in 
data collection procedures and laboratory methods. Additionally, 
differences in healthcare seeking behaviour may influence the 
findings between countries.
Currently diagnostic specimens are collected from patients 
presenting with ILI or ARI. Although ILI and/or ARI case definitions 
have been used for the detection of influenza for many years, this 
may not be the optimal clinical indicator for RSV. To investigate 
the clinical impact and determine the burden of illness of RSV one 
should extend the diagnostic categories to include acute bronchitis 
and otitis media [29]. This may become feasible with the movement 
towards sentinel networks based on electronic data.
We presented the progress in RSV surveillance based on an 
influenza surveillance network and data collected for six countries. 
This illustrated the feasibility of reporting RSV data and showed 
that a proportion of about 4-18% of the patients were infected with 
RSV. Sentinel monitoring of RSV and influenza virus is important 
and may even be extended to other respiratory viruses as the 
development of multiplex PCR [30] facilitates the detection of other 
causative agents of respiratory illness. All countries are encouraged 
to test their specimens for RSV and improvements can be made as 
less than half of the countries participating in EISS had reported 
these data. Furthermore, swabbing procedures should be further 
harmonised and regular quality control of laboratory methods 
should be performed. When these criteria are met, surveillance 
of RSV and influenza virus will contribute to a better insight into 
the burden of respiratory diseases and may be used by healthcare 
organisations to decide on the timing of palivizumab prophylaxis 
for RSV in Europe. Overall, this paper illustrated that an existing 
influenza surveillance system can be relatively easily broadened 
to include the surveillance of RSV and may be extended to other 
viruses in the future.
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